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Obesity and the metabolic syndrome are characterized by
chronic, low-grade inflammation mainly originating from
expanding adipose tissue and resulting in inhibition of insulin
signaling and disruption of glycemic control. Transgenic mice
expressing human interleukin 37 (IL-37), an anti-inflammatory
cytokine of the IL-1 family, are protected againstmetabolic syn-
drome when fed a high-fat diet (HFD) containing 45% fat. Here,
we examined whether treatment with recombinant IL-37
ameliorates established insulin resistance and obesity-induced
inflammation. WT mice were fed a HFD for 22 weeks and then
treated daily with IL-37 (1 g/mouse) during the last 2 weeks.
Compared with vehicle only–treated mice, IL-37–treated mice
exhibited reduced insulin in the plasma and had significant
improvements in glucose tolerance and in insulin content of the
islets. The IL-37 treatment also increased the levels of circulat-
ing IL-1 receptor antagonist. Cultured adipose tissues revealed
that IL-37 treatment significantly decreases spontaneous secre-
tions of IL-1, tumor necrosis factor  (TNF), and CXCmotif
chemokine ligand 1 (CXCL-1). We also fed mice a 60% fat diet
with concomitant daily IL-37 for 2 weeks and observed
decreased secretion of IL-1, TNF, and IL-6 and reduced
intracellular levels of IL-1 in the liver and adipose tissue, along
with improved plasma glucose clearance. Compared with vehi-
cle treatment, these IL-37–treatedmice had no apparent weight
gain. In human adipose tissue cultures, the presence of 50 pM
IL-37 reduced spontaneous release of TNF and 50% of
lipopolysaccharide-induced TNF. These findings indicate
that IL-37’s anti-inflammatory effects can ameliorate estab-
lished metabolic disturbances during obesity.
The incidence of obesity has dramatically increased world-
wide during recent decades (1). The presence of obesity leads
to an increased risk for the development of the metabolic
syndrome, cardiovascular disease, and type 2 diabetes (2,
4) (https://www.nhlbi.nih.gov/health-topics/overweight-and-
obesity; accessed July 24, 2018) and is directly associated with
all-cause mortality (5). However, despite advocated lifestyle
changes and efforts to reduce obesity and its effects onmorbid-
ity and mortality, the number of overweight and obese individ-
uals continues to increase globally (1). Therefore, developing
new approaches to resolve the detrimental metabolic effects of
obesity and type 2 diabetes remains a high priority. During the
development of obesity and the concomitant metabolic stress,
adipose tissue develops a state of chronic low-grade inflamma-
tion. Inflammation in adipose tissue is characterized by
increased production of pro-inflammatory cytokines, such as
IL-1,8 IL-6, and TNF, and an increase in macrophage num-
bers (6, 7). These pro-inflammatory cytokines directly interfere
with insulin signaling (8–10), resulting in insulin resistance.
The interleukin-1 family of cytokines plays a critical role in
the regulation of metabolic inflammation (11), particularly by
pro-inflammatory members IL-1 (12–14) and IL-1 (15, 16).
In contrast, the IL-1 receptor antagonist (IL-1Ra), also a mem-
ber of the IL-1 family, represents an endogenousmechanism to
reduce IL-1–driven inflammation (17–19). In clinical studies of
recombinant IL-1Ra (anakinra) in patients with type 2 diabetes,
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hemoglobin A1C, ameasure of elevated blood sugar, is reduced
compared with placebo-treated subjects (20). Similar reduc-
tions have been reported in clinical trials of neutralizing anti-
bodies to IL-1 (21–23) and to IL-1 (24). Another member of
the IL-1 family, IL-37, has broad anti-inflammatory properties
and also plays a role in obesity (25). For example, weight loss in
morbidly obese humans is associated with an increase in IL-37
levels (26). Mice carrying the human gene for IL-37 are pro-
tected from the development of obesity-induced inflammation
and insulin resistance when challenged with a high-fat diet
(HFD) (25). Additionally, liver and plasma lipid levels of these
mice improve comparedwithWTmice on aHFD. Importantly,
mice transgenic for human IL-37 and subjected toHFD are also
protected against glucose intolerance after only 4 days of HFD.
In the present study, we administered recombinant human
IL-37 to WT mice that had been subjected to HFD feeding for
22weeks.We tested the hypothesis that interventionwith IL-37
can ameliorate establishedmetabolic inflammation and insulin
resistance in the presence of obesity.
Results
Treatment with recombinant IL-37 reverses impaired insulin
signaling
To test whether treatment with IL-37 has therapeutic value
to improve insulin and glycemic control in established obesity,
mice were fed aHFD for 22weeks (Fig. 1a). Only during the last
2 weeks, mice were given vehicle or IL-37 intraperitoneally, at a
concentration of either 0.1g or 1g/mouse/day. As shown in
Fig. S1 (a–c), neither treatment had an effect on liver, epididy-
mal adipose tissue, or total body weight. However, in response
to insulin, animals treated with a daily dose of 1 g showed a
greater reduction in glucose levels, compared with vehicle-
treated mice, consistent with improved insulin sensitivity (Fig.
1b); no differences were observed in fasting glucose levels (Fig.
1c). Moreover, we observed a higher glucose clearance in mice
receiving the 1-g dose of IL-37, suggestive of improved glu-
cose tolerance compared with vehicle-treated mice (Fig. 1, d
and e). Furthermore, there was a significant decrease in fasting
insulin levels (25% reduction) in mice treated with the 1-g
dose of IL-37 (Fig. 1f), in support of improved insulin sensitivity
(27).
We next investigated whether 2 weeks of IL-37 treatment
affected the insulin-producing pancreatic islets. Pancreatic
islets were stained for insulin content, and the area of insulin
staining was quantified in a blinded fashion. Although there
were a similar number of pancreatic islets in the animals (Fig.
S1d), the total area of the insulin-producing islets was less (40%
reduction) in IL-37–treatedmice (Fig. 1, g and h), similar to our
earlier observation in IL-37tg mice (25). Additionally, staining
for the macrophage marker F480 revealed that islets from
IL-37–treated mice contained lower numbers of macrophages
(Fig. 1i). Although the reduced number of islet macrophages
did not reach statistical significance, the reduction of nearly
50% was observed at the 1-g dose (p  0.056) as well at the
0.1-g dose (p 0.062).
To investigate whether IL-37 had direct effects on pancreatic
beta-cells, INS-1 cells were pre-exposed to IL-37 overnight
before exposure to either cytokines (IL-1 alone or in combi-
nation with TNF or glucolipotoxic conditions (GLT). IL-37 or
IL-1Ra pre-exposure did not affect the cell viability in the
absence of cytokines orGLT (Fig. 1, j and k). As expected, IL-1
in the absence or presence of TNF robustly reduced cell via-
bility, also significantly although to a lesser extent than reduced
by GLT. Whereas IL-1Ra completely blocked cytokine but not
GLT toxicity, IL-37 exhibited no effect on cytokine- or GLT-
induced cell death.
Because cell death can be an insensitive measure of IL-37
bioactivity, we also determined accumulated nitrite in the cell
supernatants as a surrogate forNOproduction. Being produced
as a consequence of NF-B–dependent expression of inducible
NO synthase, accumulated nitrite is a validated proxy for
NF-B signaling. Neither IL-37 nor IL-1Ra increased NO pro-
duction (Fig. 1l). As expected, cytokines but not GLT strongly
induced NO production. Whereas IL-1Ra completely pre-
vented cytokine-induced NO formation, IL-37 was ineffective.
Neither IL-37 nor IL-1Ra affected NO production in conjunc-
tion with GLT (Fig. 1, l andm). Together, these results suggest
that IL-37 changes the pancreatic islet inflammatory environ-
ment without direct effects on the beta-cells.
We also compared the effects of IL-37 administered to WT
mice with that in IL-37tg mice after 8 weeks of HFD. We
observed similar improvements in insulin sensitivity between
recombinant IL-37–treated WT mice and IL-37tg mice when
compared with control mice (Fig. S1e). A mild reduction was
observed in glucose levels after a 4-h fast in IL-37tg mice
when compared with control mice (Fig. S1f). These data sug-
gest that treatment with IL-37 improves insulin and glucose
homeostasis.
IL-37 reduces adipose tissue inflammation in vivo inmice and
ex vivo in humans
Insulin resistance and glucose intolerance are strongly linked
to adipose tissue inflammation (11, 28, 29). Therefore, we
determined whether administration of IL-37 affected adipose
tissue secretion of cytokines after 22weeks ofHFD.As shown in
Fig. 2a, total tissue levels of IL-1 were not significantly
reduced in the adipose tissue from mice treated with IL-37.
However, the spontaneous release of the pro-inflammatory
cytokines IL-1, CXCL-1 (KC), and TNF was significantly
reduced in the adipose tissue of the IL-37–treated mice, com-
pared with vehicle-treated mice (Fig. 2, b–d). In contrast, the
levels of anti-inflammatory cytokine IL-1Ra were not reduced
(Fig. 2e).
Adipose tissue macrophages are major contributors to
obesity-induced inflammation (4). Therefore, we evaluated
whether IL-37 affected the number of macrophages in the
eWAT of the HFD-challengedmice. Using F480 staining, there
were no differences in the presence of crownlike structures
(multiplemacrophages surrounding an adipocyte) (Fig. 2f) or in
the number of macrophages (Fig. S2 (a) and Fig. 2g). Moreover,
mRNA analyses of eWAT did not reveal differences in known
monocyte/macrophage markers (Fig. S2, b–e). Together, this
suggests that IL-37 decreased the spontaneous secretion of
pro-inflammatory cytokines without affecting the number of
macrophages in the adipose tissue.
IL-37 treatment ameliorates establishedmetabolic syndrome
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Figure 1. Treatment with recombinant human IL-37 ameliorates glucose and insulin tolerance in obese mice.WTmice were subjected to 22 weeks of
HFD. During the last 14 days themicewere injectedwith recombinant IL-37 or vehicle. a, meanbodyweight over time. b, ITT, relative to t 0. c, fasting glucose
levels before ITT. d, glucose tolerance test (IPGTT), relative to t 0; e, fasting glucose levels before GTT. f, fasting insulin levels at sacrifice. g, mean proportion
of the insulin-producing islets in the pancreas, compared with the total area of the pancreas. h, representative histological insulin-stained sections of pan-
creata. i, representative histological F480-stained sections of pancreata; macrophages were quantified per islet. INS-1 cells were cultured and pre-exposed to
IL-37or vehicle overnight, or to IL-1Ra for 1 h. j and k, INS-1 cell viability after IL-1 aloneor togetherwith TNF (cytokinemixture,Cyt) (j) or challengedwithGLT
(k). Cellswere cultured for 24 h. Cell viabilitywas assessedusing the alamarBlue assay (n 4 (cytokines) andn 3 (GLT)). l andm, nitrite production in response
to IL-1 alone or together with TNF (l) or GLT (m), n 3. *, p 0.05; **, p 0.01, as tested with ANOVA. n 10mice/group. Data are shown as means S.E.
(error bars).
IL-37 treatment ameliorates establishedmetabolic syndrome
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To expand on this finding, we incubated human adipose
tissue explants in vitro for 24 h with IL-37. Similar to the data
in mice, IL-37 reduced spontaneous as well as lipopolysac-
charide (LPS)-stimulated secretion of TNF (Fig. 2h).
Together, these data demonstrate that IL-37 shifts the pro-
inflammatory status in the adipose tissue toward a more
anti-inflammatory state.
IL-37 treatment improvesmetabolic markers
We next assessed whether the effects of IL-37 treatment on
metabolic and inflammatory markers are associated with
changes in circulating parameters related tometabolism or adi-
pose tissue health. First, we investigated circulating adiponec-
tin levels, as these were markedly elevated in the circulation of
Figure 1—continued
IL-37 treatment ameliorates establishedmetabolic syndrome
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IL-37tg mice subjected to HFD (25). As shown in Fig. 3a,
serum adiponectin levels increased, and this increase was
statistically significant in the low-dose IL-37 treatment
group. No differences were found in circulating leptin levels
(Fig. 3b) or in plasma cholesterol levels (Fig. 3c). However,
levels of triglycerides were reduced after IL-37 treatment
(Fig. 3d). We also observed a 75% increase in plasma levels of
the anti-inflammatory cytokine IL-1Ra in mice receiving the
high-dose IL-37 treatment compared with vehicle-injected
mice (Fig. 3e). These data suggest that IL-37 improves sev-
Figure2. IL-37 inhibits the secretionof inflammatory cytokines inepididymalwhiteadipose tissue.Micewere fed22weeksofHFDand received2weeks
of daily IL-37or vehicle.a, IL-1 levels in adipose tissue. 24-h spontaneous secretionof cytokineswasmeasured fromculturedadipose tissue.b, IL-1; c, CXCL-1;
d, TNF; e, IL-1Ra. f, number of crown-like structures in adipose tissue sections stained for F480. g, representative images per group are shown. h, human
subcutaneous adipose tissue was incubated with increasing concentrations of IL-37 (pg/ml) as indicated as well as with 50 ng/ml LPS. TNF secretion was
determined in the supernatants by a specific human ELISA. *, p 0.05; **, p 0.01, as tested with ANOVA. n 10 mice/group for all experiments. Data are
shown as means S.E. (error bars).
IL-37 treatment ameliorates establishedmetabolic syndrome
14228 J. Biol. Chem. (2018) 293(37) 14224–14236
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on M
ay 13, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
eral metabolic and anti-inflammatory markers in the
circulation.
Short-term lipotoxicity-induced insulin resistance is not
improved by IL-37 treatment
Next, we investigated whether the administration of IL-37
could prevent detrimental effects on insulin signaling and gly-
cemic control in a short-term model of HFD feeding that
impairs glucose tolerance and hepatic insulin sensitivity (30).
For this study, we fed mice a very high-fat diet with 60% of
energy from fat (vHFD). During this 14-day vHFD, IL-37 was
administered daily (1 g/mouse/day). Compared with mice
receiving daily vehicle, mice injected with IL-37 did not gain
weight during this period (Fig. 4, a–c). Consistent with this
observation, the weights of epididymal adipose tissue were
lower in mice treated with IL-37 (Fig. 4d). In addition, we
observed that the liver weights of both groups on the vHFD
were lower than for the livers of the LFD group (Fig. 4e), sug-
gesting that the lipid overload increases adipose tissue mass
rather than liver deposits in this short-term model. To assess
whether intervention with IL-37 treatment could improve glu-
cose clearance similar to the 22-week HFD intervention, mice
fed the vHFD for 10 days were then subjected to a glucose tol-
erance test. As shown in Fig. 4f, there was a small but statisti-
cally significant improvement in glucose clearance after 2 h in
the IL-37–treated mice.
Additionally, we evaluated circulating metabolic markers.
Although plasma cholesterol levels remained unchanged (Fig.
S3a), both groups on the short-term HFD displayed lower trig-
lyceride levels, whereas glucose levels in the plasma increased
Figure 3. Effect of IL-37 treatment of obese mice on blood metabolites. After 22 weeks of HFD and 2 weeks of daily IL-37 or vehicle administration,
metabolicmarkers were determined in plasma. a, adiponectin; b, leptin; c, cholesterol; d, triglycerides; e, IL-1Ra. *, p 0.05; **, p 0.01, as testedwith ANOVA.
n 10 mice/group. Data are shown as means S.E. (error bars).
Figure 4. IL-37 limits weight gain in amodel of short-term lipid overload.Mice were subjected to a LFD or very HFD and injected with recombinant IL-37
or vehicle over the courseof 14days.a, bodyweights at the start of diets;b, bodyweights at theendofdiets; c, weightgain;d, epididymal adipose tissueweight;
e, liver weight; f, intraperitoneal glucose tolerance test. *, p 0.05; **, p 0.01; ***, p 0.001 as tested with ANOVA. n 10 mice/group. Data are shown as
means S.E. (error bars).
IL-37 treatment ameliorates establishedmetabolic syndrome
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(Fig. S3, b and c). No differences were observed in adiponectin
or leptin levels (Fig. S3, d and e). Similar to the findings after 22
weeks of HFD, IL-1Ra levels in the plasma increase after IL-37
treatment, although the increasewas not statistically significant
(Fig. S3f). Cholesterol, triglycerides, and glucose levels in liver
lysates of the vHFD study are shown in Fig. S4. Together, these
data suggest that IL-37 prevents weight gain but has limited
effects on metabolic markers in the acute model of lipid
overload.
Short-term lipotoxicity-induced inflammation is responsive to
IL-37 treatment
We then evaluated the anti-inflammatory effects of IL-37 on
the liver and adipose tissue, both crucial organs in regulating
short-term lipid overload.We compared secretion of cytokines
in these tissues from both treatments after vHFD. Intracellular
content of IL-1 was reduced by 22% in cultured liver tissue
isolated from IL-37–treatedmice (Fig. 5a).Moreover, the levels
of secreted of IL-1 and IL-6 were reduced when compared
with vehicle-treated mice (Fig. 5, b and c). We also assessed
cytokine secretion from the cultured adipose tissue. Although
the levels of IL-1 and CXCL-1 were not different, the 24-h
secretion of IL-1 and TNF was significantly reduced in epi-
didymal adipose tissue from IL-37–treated mice (Fig. 5, d–g).
Similar to mice fed the standard HFD, there was no decrease in
the secretion of IL-1Ra in mice treated for 14 days with IL-37
while being fed the vHFD (Fig. 5h).
Discussion
Inflammation that occurs during obesity is detrimental for
several metabolic pathways, particularly insulin signaling and
glucose metabolism (31), thereby increasing the risk for the
development of type 2 diabetes. Using mice fed 22 weeks of a
HFD, the present study shows that treatment during the last 2
weeks with recombinant human IL-37 ameliorates established
insulin resistance and glucose intolerance. These effects of
Figure 5. The effect of recombinant IL-37during short-term lipid overloadon liver andadipose tissue inflammation.Micewere subjected to aHFD and
treated daily with IL-37 or vehicle for 14 days. Liver cells were isolated and cultured, and cytokine levels were measured. a–c, intracellular IL-1 (a), secreted
IL-1 (b), and IL-6 (c) after 24 h. In adipose tissue, intracellular IL-1 (d) and secretion of cytokines was measured after 24 h: IL-1 (e), CXCL-1 (f), TNF (g), and
IL-1Ra (h). *, p 0.05; **, p 0.01, as tested with ANOVA. n 10 mice/group. Data are shown as means S.E.
IL-37 treatment ameliorates establishedmetabolic syndrome
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IL-37 treatment were associated with restoring the balance in
the production of pro- and anti-inflammatory cytokines sys-
temically as well as in the adipose tissue. In addition, we iden-
tified beneficial changes in insulin sensitivity. These effects
identify the administration of IL-37 as a potential treatment
strategy in obesity-associated metabolic diseases. Our previous
studies in transgenic mice expressing human IL-37 (25)
revealed a role for this cytokine in preventing obesity-driven
metabolic derangement; however, the current studies provide a
proof of concept for the efficacy of IL-37 treatment once insulin
resistance has been established.
Compared with mice receiving vehicle, mice treated with a
daily dose of 1g of IL-37 for the last 2 weeks of a 22-weekHFD
intervention exhibited improvement in insulin and glucose tol-
erance challenges, reduced fasting insulin levels, and smaller
insulin-producing islets, as seen previously in the IL-37tgmice
on a HFD (25). Reduced plasma insulin levels indicate normal-
ized insulin sensitivity (27).
IL-37 broadly suppresses inflammation (32) by recruiting the
anti-inflammatory IL-1 receptor 8 (IL-1R8, formally known as
TIR8 or SIGIRR). Mice deficient in IL-1R8 are not protected
against inflammation when treated with IL-37 (33–36). IL-37
binding to IL-1R8 decoys MyD88 and limits signaling down-
stream to IL-1 family andToll-like receptors (37). By binding to
IL-18R and IL-1R8, IL-37 has broad anti-inflammatory
effects, as has been shown in several studies (33, 35, 38). In the
context of obesity, IL-37 induces pseudostarvation effects by
activating AMPK (25, 32) and by inhibitingmTOR (32, 33), two
important energy sensors in the cell. Metabolic stress induced
by higher glucose levels (16) can stimulate proliferation of beta-
cells, increased insulin secretion, and production of IL-1 (39)
via mechanisms involving reduced AMPK and increased
mTOR activation in beta-cells (40–42). In addition, AMPK
activators have recently been shown to improve glucose dis-
posal and homeostasis in rodents and nonhuman primates (43,
44). Because IL-37 has been shown to activate AMPK and
inhibit mTOR in other cells (25, 32, 33, 45), this property of
IL-37 may provide a hypothesis to explain why administration
of this cytokine decreases plasma insulin levels and pancreatic
islet mass.
Our data reveal that IL-37 does not directly act upon beta-
cells, suggesting that indirect pathways are involved. IL-18
receptor is not constitutively expressed in islet beta cells and
may therefore explain the lack of direct effects of IL-37 on these
cells (46). In type 2 diabetes, IL-1 plays an important role in
the dysfunction of the insulin-producing beta cell (47). More-
over, IL-1 induces BMP2 and BMP4 that have been shown to
reduce beta-cell function. By reducing levels of IL-1 and
therefore BMP2, IL-37 may therefore improve beta-cell func-
tion (48). Together, this suggests that administration of IL-37
can reverse HFD-induced metabolic stress upon the islets,
probably via a reduction of infiltrating macrophages and
thereby production of beta-cell cytotoxic IL-1 and induction of
BMP2, resulting in improved insulin homeostasis. Neverthe-
less, because IL-1Ra improves both beta-cell function and insu-
lin sensitivity in most animal models (49–51), the increase in
IL-1Ra (Fig. 3e) may contribute to the anti-inflammatory and
metabolic effects of IL-37.
We found that mice receiving 1 g of IL-37 have smaller
islets than vehicle-treated mice fed a HFD (Fig. 1, g and h).
These findingswere also observed in previous studies in IL-37tg
mice (25). Humans with type 2 diabetes and rats with insulin
resistance have increased numbers of islet-associated macro-
phages (51), resulting in an increased inflammatory environ-
ment (50). In parallel, metabolic stress increases the size of pan-
creatic islets (52). It is likely that a decrease in the secretion of
IL-1 from adipose tissue and an increase in systemic levels of
IL-1Ra would offset inflammation in the pancreatic islets and
contribute to a reduction in compensatory beta-cell hyperpla-
sia (16, 47). Indeed, mice that received IL-37 had lower num-
bers of macrophages in their pancreatic islets. Thus, together
with the improved insulin tolerance test (ITT) and glucose tol-
erance test (GTT), these data suggest that intervention with
IL-37 improves insulin homeostasis in established obesity.
However, it remains unknown whether IL-37 could directly
influence glucose-stimulated insulin secretion. It is known that
another anti-inflammatory cytokine IL-1Ra plays an important
role in beta-cell insulin secretion and proliferation, as deletion
of beta-cell–derived IL-1Ra impairs glucose homeostasis, beta-
cell proliferation, and insulin secretion (53). Interestingly,
IL-37–treated mice fed with HFD in this study presented a
decrease in adipose tissue inflammatory cytokines and an
increase in the anti-inflammatory IL-1Ra. This is consistent
with what is observed in IL-37tg mice with HFD (25). In addi-
tion, we observed that both IL-37tgmice (25) and recombinant
IL-37–treated mice fed with HFD showed a decreased area of
insulin-producing pancreatic islets. Future studies would be
required to study glucose-stimulated insulin secretion in these
models.
As adipose tissue inflammation is a key contributor to obesi-
ty-induced insulin resistance, a relevant observation in this
study is that IL-37 globally reduces inflammation in adipose
tissue, as reflected by cytokine release. Decreased spontaneous
IL-1, CXCL-1, and TNF secretion from the epididymal adi-
pose tissue of IL-37–treated mice is relevant to improved met-
abolic changes. The reduced spontaneous TNF secretion in
mouse adipose tissue was also observed in human adipose tis-
sue. Secretion of pro-inflammatory cytokines by adipose tissue
leads to local and whole-body insulin resistance (9, 29, 54, 55).
Also, increased IL-1 secretion from the adipose tissue induces
hepatic insulin resistance (56). These observations indicate that
IL-37 administration restores established obesity-inducedmet-
abolic disturbances, at least by dampening local and systemic
inflammation, thus contributing to improved systemic insulin
sensitivity. Interestingly, the reduction of pro-inflammatory
cytokine secretion was not achieved by reducing the number of
macrophages. It is possible that IL-37 skewed the development
of infiltrating macrophages toward a more anti-inflammatory
phenotype, as has been reported by others (32, 38). IL-37 has
been shown to reducemacrophage inflammatory activity, espe-
cially when polarized toward a pro-inflammatory phenotype
(38). Because macrophages in adipose tissue are part of the
inflammation and result in insulin resistance (4, 57), IL-37 is an
attractive novel therapeutic in obesity and diabetes.
We also investigated whether IL-37 restores metabolic
abnormalities resulting from a short-term (2-week) lipid over-
IL-37 treatment ameliorates establishedmetabolic syndrome
J. Biol. Chem. (2018) 293(37) 14224–14236 14231
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on M
ay 13, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
load that results in glucose intolerance andhepatic insulin resis-
tance (30, 58). A key finding was thatmice simultaneously chal-
lengedwith vHFD and treatedwith IL-37 did not gain weight as
compared with vehicle-injected mice on the same vHFD. This
finding may be due to energy expenditure in adipose tissue and
muscle (25, 45), adipose tissue browning, or appetite change,
which are known to regulate body weight and high-fat diet–
induced obesity in mice (59–61). In addition, as discussed
above, it would be intriguing to further study the effect of IL-37
on glucose-stimulated insulin secretion in this vHFD model as
well. Also, in the liver as well as adipose tissue of IL-37–treated
mice, the levels of secreted IL-1 and TNF and intracellular
IL-1were reduced.Although IL-37 treatment reduced inflam-
matory cytokine production in liver and adipose tissue, cyto-
kine levels in mice on the short-term diet were 2–10 times
lower compared with the 22-week intervention. These findings
suggest that the model of short-termHFD and lipid overload is
not highly inflammatory (62). We speculate that the inflamma-
tory trait in this model, as opposed to the lipid toxicity that
causes glucose intolerance (63), might not have been suffi-
ciently severe for IL-37 to fully exert its anti-inflammatory
effects. Interestingly, IL-37tg mice showed an improvement
when challenged with vHFD for 2 weeks (25). Because IL-37
in the IL-37tg model is also present intracellularly, as com-
pared with the exogenous administration of IL-37 used in the
current studies, this difference may account for the observed
differences.
We also examined the effects of a lower dose of IL-37 (0.1
g/mouse/day) because low picomolar concentrations of IL-37
suppressed LPS-induced IL-1, IL-6, and TNF from human
M1 differentiatedmacrophages in vitro (38). Also, in amodel of
acute lung inflammation, a single dose of 0.1g protectedmice
against damaging neutrophil infiltration and resulted in lower
lung cytokine levels (34). A dose of 0.1 g/mouse corresponds
to 2 g/kg, whereas a dose of 1 g/mouse corresponds to 20
g/kg. Of note, these low concentrations confirm that IL-37 is
effective at very low doses (34, 38). By comparison, leptin
requires dosing of 100 g/kg (64), and rapamycin is used at 1.5
mg/kg (65) to reduce fasting serum insulin and glucose levels in
genetically obese mice (ob/ob) and body weight of HFD-fed
WT mice, respectively. Pretreatment with IL-37 effectively
reduced inflammation in acute experimental models (3). These
data on mice subjected to HFD indicate great promise of IL-37
in settings in the treatment of established chronic inflamma-
tion, such as obesity and diabetes.
Together, these findings indicate that treatment with IL-37
counteracts inflammation during obesity and ameliorates glu-
cose and insulin homeostasis in mice. These results highlight
IL-37 as a potential therapeutic to ameliorate metabolic distur-
bances during obesity. Therefore, follow-up studies in humans
arewarranted, to gainmore insight into the role of IL-37 in type
2 diabetes.
Materials andmethods
Human samples
Subcutaneous adipose tissues were obtained from consent-
ing healthy donors (25). The studies were approved by the eth-
ical committee of the Radboud University Medical Centre at
Nijmegen and abide by the Declaration of Helsinki principles.
Mice and diets
Eight-week-old male C57BL/6 mice were purchased from
Jackson Laboratories (Bar Harbor, ME). The mice were housed
in a pathogen-free facility of the University of Colorado Denver
Anschutz Medical Campus. Five mice were housed per cage,
with water and food available ad libitum. The mice were ran-
domly allocated to a group. Animal protocols were approved by
the University of Colorado animal care and use committee.
Models for high-fat diet
In each experiment, mice first received a run-in period for 2
weeks of a LFD (10% of energy derived from fat, D12450B;
Research Diets, Inc., New Brunswick, NJ). Mice were then ran-
domized to a LFD or a HFD, and body weight was recorded
weekly. The HFD for the 8- and 20-week diet studies contained
45% energy derived from fat (D12451; ResearchDiets, Inc.). For
the short-term (2-week) diet study,mice received the sameLFD
run-in period but were subsequently challenged with LFD or
vHFD (containing 60% energy from fat, D12492; Research
Diets) for 14 days. After sacrifice under anesthesia, liver, pan-
creas, and epididymal adipose tissue were removed, and blood
was collected. Tissue weight was measured and, unless stated
otherwise, tissue was snap-frozen in liquid nitrogen within 5
min of sacrifice. During the last 2 weeks, mice received intra-
peritoneal injections of PBS vehicle or IL-37, at a concentration
of either 0.1 g/mouse/day or 1 g/mouse/day.
Recombinant human interleukin-37
The recombinant IL-37 used for these studies was obtained
from Bio-Techne (Minneapolis, MN). The recombinant IL-37
was expressed in Escherichia coli with an N terminus at valine
46 (residues 46–218), as reported previously (38).
Insulin/glucose tolerance test
Insulin and glucose tolerance tests were performed at least 2
days before sacrifice and with at least 3 days between both tol-
erance tests. Before the ITT, mice were fasted for 4 h, and insu-
lin (0.75 units/kg, NovoLogFlexPen, Novo Nordisk Inc.,
Princeton, NJ) was administered intraperitoneally. Before the
GTT, mice were fasted for 6 h, and glucose (2 g/kg D-glucose,
Sigma-Aldrich) was given intraperitoneally. All tests started
between 9:00 and 10:00 a.m., and mice were treated/assessed
randomly. Accu-Chek glucometers (Roche Diagnostics) were
used to determine glucose levels during the ITT and GTT,
using the Accu-Chek Smartview strips (Roche Diagnostics).
Adipose tissue culture
Fresh mouse epididymal adipose tissue was washed in ice-
cold DMEM (32430, Thermo Fisher Scientific) under sterile
conditions and cut into small 1-mm3 pieces. 100 mg of the
adipose tissue was incubated in a 48-well plate for 24 h at 37 °C
in 500 l of DMEM (Thermo Fisher Scientific) in the presence
of 10% FCS (Thermo Fisher Scientific) and 1% penicillin/strep-
tomycin (Thermo Fisher Scientific). After 24 h, the supernatant
and adipose tissue were collected and stored at80 °C.
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The human subcutaneous adipose tissue was cultured anon-
ymously in a similar culture condition as above and stimulated
with 50 ng/ml LPS (from E. coli serotype O55:B5, Sigma) with-
out or with increasing concentrations of IL-37. After 24 h, the
supernatants were collected and stored at80 °C.
Liver cell culture
After sacrifice, livers were harvested and weighed. A small
piece of liver was cut, weighed, and minced with a sterile surgi-
cal scalpel in RPMI 1640 (Thermo Fisher Scientific) containing
1% penicillin/streptomycin. The minced liver tissue was then
macerated through a sterile 70-nm cell filter with the plunger
end of a sterile plastic syringe. Additional RPMI was added to
collect the cell suspension in a 50-ml tube. Cells were washed
twice in RPMI (350  g for 10 min) and suspended in RPMI
with 1% penicillin/streptomycin and 5% FCS at a concentration
of 12.5 mg/ml. One ml was added to each well of a 24-well flat
bottom plate and cultured at 37 °C in a CO2-enriched environ-
ment for 24 h. Supernatants were collected for cytokine deter-
minations, and cells were lysed with 250 l of 0.5% Triton
X-100.
Insulin-producing cells
INS-1 cells were a gift from Claes Wollheim (Department of
Cell Physiology and Metabolism, University Medical Center,
Geneva, Switzerland). Cells were maintained in RPMI 1640
mediumwith GlutaMAX (Gibco catalog no. 61870-010) sup-
plemented with 10% fetal bovine serum (Life Technologies
catalog no. 26140079), 100 units/ml penicillin, 100 g/ml
streptomycin (Gibco, catalog no. 15140-122), and 50 M
-mercaptoethanol (Gibco, catalog no. 31350-010) (complete
medium) at 37 °C in a humidified atmosphere containing 5%
CO2.
INS-1 cell exposures
Cytokines—INS-1 cells were pre-exposed to 1 ng/ml IL-37 or
vehicle for overnight incubation or 10 mg/ml IL-1Ra for 1 h.
Subsequently, equal volumes of vehicle, 150 pg/ml recombi-
nant mIL-1 (R&D Systems catalog no. 401-ML-005), or cyto-
kine mixture (150 pg/ml recombinant mIL-1 plus 10 ng/ml
recombinant hTNF (Peprotech catalog no. 300-01A) were
added for 24 h.
GLT—The fatty acid palmitate (Invitrogen) was dissolved in
80% ethanol and conjugated to BSA for at least 4 h at 37 °C in a
3:1molar ratio of fatty acids to BSA in completemedium. Com-
plete medium with BSA-conjugated palmitate (0.5 mM palmi-
tate) was to added endotoxin-free glucose (Invitrogen) to
obtain a final concentration of 25 mM. Control vehicle con-
tained BSA and ethanol in concentrations identical to the final
concentrations in the glucolipotoxic conditions.
INS-1 cell viability assay
Fifty thousand INS-1 cells were seeded in a 96-well plate for
24 h before exposure to either cytokines, GLT, or respective
vehicles for 24 h. Next, the wells were washed in 200 l of
PBS before the addition of 110 l of PBS containing 10%
alamarBlueTM (Invitrogen, catalog no. DAL1100). The plate
was then wrapped in aluminum foil and incubated for 3 h at
37 °C in a humidified atmosphere containing 5% CO2 before
reading in a microplate reader at 570/595 nm.
Nitrite accumulation
Nitrite (NO2), a surrogate measure of NO, was measured in
INS-1 cell supernatants by mixing Griess reagent (0.1% (w/v)
naphthylethene diamine hydrochloride; Sigma) in H2O2 with
1% (w/v) sulfanilamide (Bie and Berntsen) and diluted to 5%
(v/v) with culture medium (1:1, v/v) before the absorbance was
measured at 550 nm. Accumulated nitrite was calculated using
a NaNO2 standard curve.
ELISA
Levels of insulin (Crystal Chem Inc.) and levels of adiponec-
tin, leptin, IL-1, IL-1, IL-1Ra, IL-6, CXCL-1, and TNFwere
measured with an ELISA (Bio-Techne) according to the man-
ufacturer’s protocols.
Quantitative PCR
Total mRNA was isolated from adipose tissue using TRIzol
(Invitrogen), according to the manufacturer’s instructions.
mRNA was reverse-transcribed (iScript cDNA synthesis kit,
Bio-Rad). RT-PCR was performed using specific primers with
power SYBR Green master mix (Applied Biosystems, Foster
City, CA) using the Step-one real-time PCR system (Applied
Biosystems). 36B4 was used as a housekeeping gene. Mouse
species primers usedwere as follows: 36B4, AGCGCGTCCTG-
GCATTGTGTGG (forward) and GGGCAGCAGTGGTG-
GCAGCAGC (reverse); CD68, CCAATTCAGGGTGGAAG-
AAA (forward) and CTCGGGCTCTGATGTAGGTC (reverse);
F480, CTTGGCTATGGGCTTCCAGTC (forward) and GCA-
AGGAGGACAGAGTTTATCGTG (reverse); caspase-1, GGG-
ACCCTCAAGTTTTGCC (forward) and GACGTGTACGA-
GTGGTTGTATT (reverse).
Lipids and glucose
Cholesterol, triglycerides, and glucose were measured enzy-
matically (Liquicolor, Human GmbH, Wiesbaden, Germany)
using the manufacturer’s protocols.
Immunohistochemistry
Immunohistochemistry for adipose tissue and pancreas was
performed as described previously (25). Briefly, paraffin-em-
bedded epididymal white adipose tissue was cut at 8 m and
deparaffinized and rehydrated in Clearene before ethanol and
PBS rehydration. F480 antibody was used for detection of
macrophages/monocytes (Serotec, Puchheim, Germany).
Visualization of the proteins was done using 3,3-diaminoben-
zidene for 5min.Negative controlswere stained for the primary
antibody. In adipose tissue, the total adipocytes, macrophages,
and crownlike structures were counted in3 images per tissue.
The images made with a light microscope were 1.6  2.0 mm,
and1000 adipocytes were counted per animal.
Sections of the pancreas were cut at 5 m and stained for
insulin (sc9168, Santa Cruz Biotechnology, Heidelberg, Ger-
many) to visualize pancreatic islets. F480 antibody was used for
detection of macrophages/monocytes (Serotec). Five pictures
of 1.6 2.0 mm were taken and used to quantify total pancre-
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atic area with ImageJ or the number of macrophages in the
sections. Also, the number and (total) area of insulin-producing
islets were determined with ImageJ. Total area of islets was
divided by the total area of the pancreas per animal to deter-
mine the relative area of insulin-producing islets. Researchers
were blinded for the experimental conditions when scoring the
samples.
Statistical analysis
Data are shown as mean  S.E. Differences between groups
were analyzed with Student’s t test, and differences among
more than two groups were tested with ANOVA, with post hoc
Bonferroni tests in GraphPad Prism version 6.0.
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